• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CAPIVASERTIB Drug Record

  • Summary
  • Interactions
  • Claims
  • CAPIVASERTIB chembl:CHEMBL2325741 Antineoplastic

    Alternate Names:

    AZD5363
    CAPIVASERTIB
    AZD-5363
    AZD 5363
    AZC5363
    CC-638
    pubchem.compound:25227436
    chemidplus:1143532-39-1
    drugbank:12218
    chembl:CHEMBL2325741

    Drug Info:

    Notes catalytic inhibitor
    Drug Class Kinase Inhibitors
    (3 More Sources)

    Publications:

    Davies et al., 2012, Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background., Mol. Cancer Ther.
    De Velasco et al., 2016, Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer., Oncotarget
    Ribas et al., 2015, AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo., Mol. Cancer Ther.
    Li et al., 2013, The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere., J Transl Med
    Yoon et al., 2009, Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells., Mol. Cancer Ther.
    Hyman et al., 2017, AKT Inhibition in Solid Tumors With AKT1 Mutations., J. Clin. Oncol.
    Davies et al., 2015, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors., Mol. Cancer Ther.
    Weller et al., 2017, Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363., J. Natl. Cancer Inst.
    Tamura et al., 2016, Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors., Cancer Chemother. Pharmacol.
    Kong et al., 2016, Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors., Clin. Cancer Res.
  • CAPIVASERTIB   AKT1

    Interaction Score: 0.95

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    Evidence Type Actionable
    Approval Status Phase I

    PMIDs:
    28376212 28489509 26351323 26931343


    Sources:
    MyCancerGenome ClearityFoundationClinicalTrial JAX-CKB CIViC TTD OncoKB

  • CAPIVASERTIB   AKT3

    Interaction Score: 0.62

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial TTD

  • CAPIVASERTIB   PIK3CA

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Pdx
    Approval Status Preclinical - Cell culture
    Response Type predicted – sensitive

    PMIDs:
    26116361 24088382 19755509 22294718 28489509


    Sources:
    JAX-CKB CIViC

  • CAPIVASERTIB   AKT2

    Interaction Score: 0.31

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • CAPIVASERTIB   PTEN

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    22294718 26910118


    Sources:
    JAX-CKB CIViC

  • CAPIVASERTIB   FGFR3

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    26351323


    Sources:
    JAX-CKB

  • CAPIVASERTIB   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type stomach cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24088382 19755509


    Sources:
    JAX-CKB

  • CAPIVASERTIB   MTOR

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26490311


    Sources:
    CIViC

  • CAPIVASERTIB   TP53

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type prostate cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26910118


    Sources:
    JAX-CKB

  • MyCancerGenome: AZD5363

    • Version: 20-Jun-2017

    Alternate Names:
    AZD5363 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors
    Notes catalytic inhibitor

    Publications:

  • JAX-CKB: AZD5363

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Ribas et al., 2015, AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo., Mol. Cancer Ther.
    Yoon et al., 2009, Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells., Mol. Cancer Ther.
    Li et al., 2013, The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere., J Transl Med

  • CIViC: CAPIVASERTIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Davies et al., 2015, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors., Mol. Cancer Ther.
    Hyman et al., 2017, AKT Inhibition in Solid Tumors With AKT1 Mutations., J. Clin. Oncol.
    Li et al., 2013, The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere., J Transl Med

  • TTD: AZD5363

    • Version: 2020.06.01

    Alternate Names:
    D01ZAQ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2325741

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: AZD5363

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: AZD5363

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21